Confo Therapeutics Doses First Subjects in Phase 1 Clinical Trial of CFTX-1554 for the Treatment of Neuropathic Pain

Confo Therapeutics Doses First Subjects…

Confo Therapeutics Expands Patent Estate for ConfoBody®-based GPCR Screening Platform

Confo Therapeutics Expands Patent Estate…

Confo Therapeutics Enters Collaborative Agreement with Regeneron

Confo Therapeutics Enters Collaborative Agreement…

Confo Therapeutics Establishes Medical Advisory Board

Confo Therapeutics Establishes Medical Advisory…

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Confo Therapeutics Announces Selection of…

Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director

Confo Therapeutics Expands Board with…

Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer

Confo Therapeutics Appoints Paolo Vicini…

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

FierceBiotech names Confo Therapeutics as…

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

Ghent, Belgium, and Dresden, Germany…

Confo Therapeutics receives €1.7 million grant from VLAIO

Ghent, Belgium, 20 June 2019…